IPSC
Century Therapeutics, Inc.
Price Chart
Latest Quote
$2.31
+0.02 (+0.66%)
Current Price
| Previous Close | $2.29 |
| Open | $2.29 |
| Day High | $2.50 |
| Day Low | $2.29 |
| Volume | 696,852 |
Stock Information
| Shares Outstanding | 180.35M |
| Total Debt | $48.02M |
| Cash Equivalents | $134.80M |
| Net Income | $-107.78M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $415.72M |
| EPS (TTM) | $-1.14 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $326.23M |
| Income | $-107.78M |
| Book/sh | $1.47 |
| Cash/sh | $0.75 |
| Employees | 78 |
Financial Ratios
| Quick Ratio | 10.04 |
| Current Ratio | 10.25 |
| Debt/Eq | 18.14 |
Returns & Margins
| ROA | -22.28% |
| ROE | -42.67% |
Ownership
| Insider Ownership | 12.06% |
| Institutional Ownership | 78.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.04 |
| P/B | 1.57 |
Analyst Data
| Recommendation | none |
| Target Price | $4.75 |
Technical Indicators
| SMA20 | $2.25 |
| SMA50 | $2.28 |
| SMA200 | $1.55 |
| RSI | 55.68 |
| ATR | 0.1694 |
| Shares Float | 97.86M |
| Short Float | 6.96% |
| Short Ratio | 16.45 |
| Volatility | 1.57 |
| Rel Volume | 0.71 |
Performance History
| Week | +2.44% |
| Month | +6.22% |
| Quarter | +11.35% |
| 6 Months | +168.34% |
| YTD | +131.66% |
| Year | +287.39% |
| 3 Years | -33.57% |
| 10 Years | -89.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $2.31 | 696,852 |
| 2026-06-24 | $2.29 | 1,104,600 |
| 2026-06-23 | $2.41 | 1,259,800 |
| 2026-06-22 | $2.30 | 965,200 |
| 2026-06-18 | $2.29 | 579,800 |
| 2026-06-17 | $2.25 | 959,700 |
| 2026-06-16 | $2.18 | 786,000 |
| 2026-06-15 | $2.30 | 1,081,700 |
| 2026-06-12 | $2.25 | 701,900 |
| 2026-06-11 | $2.24 | 692,900 |
| 2026-06-10 | $2.12 | 722,300 |
| 2026-06-09 | $2.21 | 837,100 |
| 2026-06-08 | $2.12 | 578,900 |
| 2026-06-05 | $2.13 | 1,902,400 |
| 2026-06-04 | $2.20 | 512,800 |
| 2026-06-03 | $2.07 | 1,755,300 |
| 2026-06-02 | $2.17 | 1,146,900 |
| 2026-06-01 | $2.36 | 910,300 |
| 2026-05-29 | $2.45 | 1,195,100 |
| 2026-05-28 | $2.38 | 1,154,300 |
| 2026-05-27 | $2.31 | 1,468,700 |
| 2026-05-26 | $2.17 | 728,100 |
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
đ° Latest News
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
Simply Wall St. âĸ 2026-06-13T13:38:25Z
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
Insider Monkey âĸ 2026-06-10T18:22:49Z
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
Insider Monkey âĸ 2026-05-01T08:18:02Z
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission
Insider Monkey âĸ 2026-01-30T19:58:25Z
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Zacks âĸ 2026-01-22T17:00:04Z
Promising Penny Stocks To Watch In January 2026
Simply Wall St. âĸ 2026-01-16T12:05:33Z
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
Zacks âĸ 2026-01-07T16:45:00Z
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Zacks âĸ 2026-01-07T13:55:02Z
3 Promising Penny Stocks With Market Caps Over $30M
Simply Wall St. âĸ 2025-12-18T18:05:06Z
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
Zacks âĸ 2025-12-09T13:55:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $109,164,000 | $6,589,000 | $2,235,000 | $5,199,000 |
| Operating Revenue | $109,164,000 | $6,589,000 | $2,235,000 | $5,199,000 |
| Expenses | ||||
| Total Expenses | $119,670,000 | $140,399,000 | $127,416,000 | $129,030,000 |
| Other Income Expense | $-6,488,000 | $-3,973,000 | $-21,748,000 | $-10,000,000 |
| Other Non Operating Income Expenses | $275,000 | $354,000 | $-383,000 | $4,420,000 |
| Net Non Operating Interest Income Expense | $7,346,000 | $13,007,000 | $12,137,000 | $2,990,000 |
| Operating Expense | $119,670,000 | $140,399,000 | $127,416,000 | $129,030,000 |
| General And Administrative Expense | $24,003,000 | $33,155,000 | $34,706,000 | $31,857,000 |
| Interest Expense | - | $0 | $540,000 | $1,200,000 |
| Interest Expense Non Operating | - | $0 | $540,000 | $1,200,000 |
| Total Other Finance Cost | - | - | - | $230,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Net Interest Income | $7,346,000 | $13,007,000 | $12,137,000 | $2,990,000 |
| Interest Income | $7,346,000 | $13,007,000 | $12,677,000 | $4,420,000 |
| Normalized Income | $-2,864,341 | $-123,147,670 | $-119,794,650 | $-120,932,000 |
| Net Income From Continuing And Discontinued Operation | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Total Operating Income As Reported | $-17,269,000 | $-138,137,000 | $-146,546,000 | $-133,831,000 |
| Net Income Common Stockholders | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Net Income | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Net Income Including Noncontrolling Interests | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Net Income Continuous Operations | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Pretax Income | $-9,648,000 | $-124,776,000 | $-134,792,000 | $-130,841,000 |
| Special Income Charges | $-6,763,000 | $-4,327,000 | $-21,365,000 | $-10,000,000 |
| Interest Income Non Operating | $7,346,000 | $13,007,000 | $12,677,000 | $4,420,000 |
| Operating Income | $-10,506,000 | $-133,810,000 | $-125,181,000 | $-123,831,000 |
| Per Share | ||||
| Diluted EPS | $-0.14 | $-1.61 | $-2.30 | $-2.27 |
| Basic EPS | $-0.14 | $-1.61 | $-2.30 | $-2.27 |
| Other | ||||
| Tax Effect Of Unusual Items | $-47,341 | $-908,670 | $-4,486,650 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $9,358,000 | $-116,179,000 | $-99,843,000 | $-111,201,000 |
| Total Unusual Items | $-6,763,000 | $-4,327,000 | $-21,365,000 | $-10,000,000 |
| Total Unusual Items Excluding Goodwill | $-6,763,000 | $-4,327,000 | $-21,365,000 | $-10,000,000 |
| Reconciled Depreciation | $13,101,000 | $13,304,000 | $13,044,000 | $8,440,000 |
| EBITDA (Bullshit earnings) | $2,595,000 | $-120,506,000 | $-121,208,000 | $-121,201,000 |
| EBIT | $-10,506,000 | $-133,810,000 | $-134,252,000 | $-129,641,000 |
| Diluted Average Shares | $86,556,515 | $78,648,958 | $59,314,389 | $57,755,842 |
| Basic Average Shares | $86,556,515 | $78,648,958 | $59,314,389 | $57,755,842 |
| Diluted NI Availto Com Stockholders | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Tax Provision | $-68,000 | $1,790,000 | $1,881,000 | $91,000 |
| Impairment Of Capital Assets | $6,763,000 | $4,327,000 | $16,365,000 | $0 |
| Research And Development | $95,667,000 | $107,244,000 | $92,710,000 | $97,173,000 |
| Selling General And Administration | $24,003,000 | $33,155,000 | $34,706,000 | $31,857,000 |
| Other Gand A | $24,003,000 | $33,155,000 | $34,706,000 | $31,857,000 |
| Other Special Charges | - | - | $5,000,000 | $10,000,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $124,736,000 | $127,162,000 | $184,750,000 | $302,738,000 |
| Total Assets | $223,704,000 | $353,216,000 | $360,691,000 | $486,544,000 |
| Total Non Current Assets | $102,935,000 | $159,165,000 | $183,697,000 | $166,823,000 |
| Other Non Current Assets | $2,359,000 | $2,772,000 | $1,979,000 | $1,979,000 |
| Non Current Prepaid Assets | $211,000 | $528,000 | $541,000 | $1,260,000 |
| Investmentin Financial Assets | $0 | $30,818,000 | $89,096,000 | $51,854,000 |
| Goodwill And Other Intangible Assets | $34,200,000 | $34,200,000 | $0 | - |
| Other Intangible Assets | $34,200,000 | $34,200,000 | - | - |
| Current Assets | $120,769,000 | $194,051,000 | $176,994,000 | $319,721,000 |
| Other Current Assets | $937,000 | $860,000 | $1,011,000 | $1,417,000 |
| Restricted Cash | $799,000 | $0 | $0 | $220,000 |
| Prepaid Assets | $1,252,000 | $2,379,000 | $1,010,000 | $1,806,000 |
| Receivables | $667,000 | $1,520,000 | $2,235,000 | $780,000 |
| Taxes Receivable | $274,000 | $266,000 | $650,000 | $0 |
| Accrued Interest Receivable | $393,000 | $1,254,000 | $1,570,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $117,114,000 | $189,292,000 | $172,738,000 | $315,498,000 |
| Cash And Cash Equivalents | $61,853,000 | $58,441,000 | $47,324,000 | $84,265,000 |
| Other Receivables | - | - | $15,000 | $780,000 |
| Debt | ||||
| Total Debt | $43,565,000 | $53,830,000 | $48,171,000 | $49,414,000 |
| Long Term Debt And Capital Lease Obligation | $40,241,000 | $48,960,000 | $46,658,000 | $42,437,000 |
| Current Debt And Capital Lease Obligation | $3,324,000 | $4,870,000 | $1,513,000 | $6,977,000 |
| Long Term Debt | - | - | - | $3,739,000 |
| Current Debt | - | - | - | $6,502,000 |
| Other Current Borrowings | - | - | - | $6,502,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $64,768,000 | $191,854,000 | $175,941,000 | $183,806,000 |
| Total Non Current Liabilities Net Minority Interest | $44,542,000 | $62,072,000 | $158,095,000 | $153,989,000 |
| Non Current Deferred Liabilities | $4,301,000 | $4,374,000 | $111,381,000 | $110,834,000 |
| Non Current Deferred Taxes Liabilities | $4,301,000 | $4,374,000 | $0 | - |
| Current Liabilities | $20,226,000 | $129,782,000 | $17,846,000 | $29,817,000 |
| Other Current Liabilities | $3,777,000 | $157,000 | $612,000 | $1,102,000 |
| Current Deferred Liabilities | $0 | $109,164,000 | $4,372,000 | $7,154,000 |
| Payables And Accrued Expenses | $13,125,000 | $15,591,000 | $11,349,000 | $14,584,000 |
| Payables | $4,773,000 | $3,075,000 | $2,741,000 | $5,454,000 |
| Accounts Payable | $4,773,000 | $3,075,000 | $2,741,000 | $5,454,000 |
| Other Non Current Liabilities | - | $8,738,000 | $56,000 | $718,000 |
| Interest Payable | - | - | $0 | $117,000 |
| Equity | ||||
| Common Stock Equity | $158,936,000 | $161,362,000 | $184,750,000 | $302,738,000 |
| Total Equity Gross Minority Interest | $158,936,000 | $161,362,000 | $184,750,000 | $302,738,000 |
| Stockholders Equity | $158,936,000 | $161,362,000 | $184,750,000 | $302,738,000 |
| Gains Losses Not Affecting Retained Earnings | $30,000 | $324,000 | $108,000 | $-2,462,000 |
| Other Equity Adjustments | $30,000 | $324,000 | $108,000 | $-2,462,000 |
| Retained Earnings | $-791,917,000 | $-782,337,000 | $-655,771,000 | $-519,098,000 |
| Other | ||||
| Ordinary Shares Number | $87,519,096 | $85,836,429 | $60,335,701 | $58,473,660 |
| Share Issued | $87,519,096 | $85,836,429 | $60,335,701 | $58,473,660 |
| Tangible Book Value | $124,736,000 | $127,162,000 | $184,750,000 | $302,738,000 |
| Invested Capital | $158,936,000 | $161,362,000 | $184,750,000 | $312,979,000 |
| Working Capital | $100,543,000 | $64,269,000 | $159,148,000 | $289,904,000 |
| Capital Lease Obligations | $43,565,000 | $53,830,000 | $48,171,000 | $39,173,000 |
| Total Capitalization | $158,936,000 | $161,362,000 | $184,750,000 | $306,477,000 |
| Additional Paid In Capital | $950,814,000 | $943,366,000 | $840,407,000 | $824,292,000 |
| Capital Stock | $9,000 | $9,000 | $6,000 | $6,000 |
| Common Stock | $9,000 | $9,000 | $6,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $40,241,000 | $48,960,000 | $46,658,000 | $38,698,000 |
| Current Deferred Revenue | $0 | $109,164,000 | $4,372,000 | $7,154,000 |
| Current Capital Lease Obligation | $3,324,000 | $4,870,000 | $1,513,000 | $475,000 |
| Current Accrued Expenses | $8,352,000 | $12,516,000 | $8,608,000 | $9,130,000 |
| Investments And Advances | $0 | $30,818,000 | $89,096,000 | $51,854,000 |
| Net PPE | $66,165,000 | $90,847,000 | $92,081,000 | $111,730,000 |
| Accumulated Depreciation | $-48,600,000 | $-36,058,000 | $-22,838,000 | $-13,655,000 |
| Gross PPE | $114,765,000 | $126,905,000 | $114,919,000 | $125,385,000 |
| Leases | $61,647,000 | $61,577,000 | $60,862,000 | $48,951,000 |
| Construction In Progress | $105,000 | $97,000 | $124,000 | $13,998,000 |
| Other Properties | $32,695,000 | $32,385,000 | $29,597,000 | $28,811,000 |
| Machinery Furniture Equipment | $20,318,000 | $32,846,000 | $24,336,000 | $33,625,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $55,261,000 | $130,851,000 | $125,414,000 | $231,233,000 |
| Non Current Deferred Revenue | - | $0 | $111,381,000 | $110,834,000 |
| Available For Sale Securities | - | $30,818,000 | $89,096,000 | $51,854,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-104,724,000 | $-110,289,000 | $-102,084,000 | $-16,552,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-103,876,000 | $-110,135,000 | $-88,348,000 | $14,052,000 |
| Cash Flow From Continuing Operating Activities | $-103,876,000 | $-110,135,000 | $-88,348,000 | $14,052,000 |
| Investing Activities | ||||
| Capital Expenditure | $-848,000 | $-154,000 | $-13,736,000 | $-30,604,000 |
| Investing Cash Flow | $107,501,000 | $47,482,000 | $61,132,000 | $-13,128,000 |
| Cash Flow From Continuing Investing Activities | $107,501,000 | $47,482,000 | $61,132,000 | $-13,128,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $173,000 | $74,563,000 | $516,000 | $27,158,000 |
| Financing Cash Flow | $173,000 | $74,563,000 | $-9,725,000 | $27,158,000 |
| Cash Flow From Continuing Financing Activities | $173,000 | $74,563,000 | $-9,725,000 | $27,158,000 |
| Net Common Stock Issuance | $173,000 | $74,563,000 | $516,000 | $27,158,000 |
| Common Stock Issuance | $173,000 | $74,563,000 | $516,000 | $27,158,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $0 | $501,000 | $3,107,000 | $1,097,000 |
| End Cash Position | $65,011,000 | $61,213,000 | $49,303,000 | $86,244,000 |
| Beginning Cash Position | $61,213,000 | $49,303,000 | $86,244,000 | $58,162,000 |
| Changes In Cash | $3,798,000 | $11,910,000 | $-36,941,000 | $28,082,000 |
| Net Investment Purchase And Sale | $108,349,000 | $57,244,000 | $74,868,000 | $17,476,000 |
| Sale Of Investment | $159,523,000 | $176,792,000 | $283,902,000 | $271,476,000 |
| Purchase Of Investment | $-51,174,000 | $-119,548,000 | $-209,034,000 | $-254,000,000 |
| Net Business Purchase And Sale | $0 | $-9,608,000 | $0 | - |
| Purchase Of Business | $0 | $-9,608,000 | $0 | - |
| Net PPE Purchase And Sale | $-848,000 | $-154,000 | $-13,736,000 | $-30,604,000 |
| Purchase Of PPE | $-848,000 | $-154,000 | $-13,736,000 | $-30,604,000 |
| Change In Working Capital | $-114,553,000 | $-9,278,000 | $9,380,000 | $123,945,000 |
| Change In Other Working Capital | $-109,164,000 | $-6,589,000 | $-2,015,000 | $118,490,000 |
| Change In Other Current Liabilities | $-4,978,000 | $-3,365,000 | $13,819,000 | $5,258,000 |
| Change In Payables And Accrued Expense | $-2,753,000 | $133,000 | $-3,091,000 | $-831,000 |
| Change In Accrued Expense | $-4,315,000 | $1,602,000 | $-730,000 | $3,957,000 |
| Change In Payable | $1,562,000 | $-1,469,000 | $-2,361,000 | $-4,788,000 |
| Change In Account Payable | $1,562,000 | $-1,469,000 | $-2,361,000 | $-4,788,000 |
| Change In Prepaid Assets | $2,342,000 | $543,000 | $667,000 | $1,028,000 |
| Other Non Cash Items | $-4,017,000 | $-668,000 | $-1,102,000 | $1,930,000 |
| Stock Based Compensation | $6,840,000 | $12,688,000 | $14,622,000 | $10,669,000 |
| Asset Impairment Charge | $6,763,000 | $4,327,000 | $16,365,000 | $0 |
| Amortization Of Securities | $-2,357,000 | $-4,812,000 | $-3,984,000 | $0 |
| Deferred Tax | $-73,000 | $870,000 | $0 | - |
| Deferred Income Tax | $-73,000 | $870,000 | $0 | - |
| Depreciation Amortization Depletion | $13,101,000 | $13,304,000 | $13,044,000 | $8,440,000 |
| Depreciation And Amortization | $13,101,000 | $13,304,000 | $13,044,000 | $8,440,000 |
| Depreciation | $13,101,000 | $13,304,000 | $13,044,000 | $8,440,000 |
| Net Income From Continuing Operations | $-9,580,000 | $-126,566,000 | $-136,673,000 | $-130,932,000 |
| Repayment Of Debt | - | $0 | $-10,241,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $-10,241,000 | $0 |
| Net Long Term Debt Issuance | - | $0 | $-10,241,000 | $0 |
| Long Term Debt Payments | - | $0 | $-10,241,000 | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-22